Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SRF231 |
Synonyms | |
Therapy Description |
SRF231 is monoclonal antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (Blood 2016 128:1843, PMID: 28286286) and may also stimulate cytotoxic T-cells (PMID: 29873856, PMID: 32345627). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SRF231 | SRF 231|SRF-231 | CD47 Antibody 31 Immune Checkpoint Inhibitor 149 | SRF231 is monoclonal antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (Blood 2016 128:1843, PMID: 28286286) and may also stimulate cytotoxic T-cells (PMID: 29873856, PMID: 32345627). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03512340 | Phase I | SRF231 | Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | Completed | USA | CAN | 0 |